Corinna Kirkpatrick
Medical · Ocean Pines, MDNPI 1609145309
Payments from drug & device makers
Across 114 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$405
- Lilly USA, LLC$360
- Amgen$216
- GSK$201
- Pfizer$118
- Abbott$105
- plus $757 from 20 others
What the payments were for
- Food & beverage$2,160100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $405 |
| Lilly USA, LLC | 21 | $360 |
| Amgen | 11 | $216 |
| GSK | 12 | $201 |
| Pfizer | 5 | $118 |
| Abbott | 5 | $105 |
| Merck | 6 | $100 |
| Novartis | 4 | $91 |
| AbbVie | 4 | $77 |
| Exact Sciences | 3 | $68 |
| Dexcom, Inc. | 2 | $42 |
| Biofire Diagnostics, LLC | 1 | $37 |
| Insulet Corporation | 1 | $35 |
| AstraZeneca | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $30 |
| Boehringer Ingelheim | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 1 | $26 |
| Mylan Specialty L.p. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Lifescan, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$120
How this compares
$2,160 in reported general payments places this provider in the 70th percentile of 543 medical providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 21 | $23,759 |
| Atorvastatin Calcium | 134 | $1,719 |
| Potassium Chloride | 41 | $1,660 |
| Rosuvastatin Calcium | 24 | $644 |
| Levothyroxine Sodium | 56 | $616 |
| Omeprazole | 53 | $612 |
| Losartan Potassium | 45 | $537 |
| Metformin Hcl | 37 | $483 |
| Metoprolol Succinate | 28 | $405 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $386 |
| Buspirone Hcl | 18 | $336 |
| Amlodipine Besylate | 60 | $322 |
| Lisinopril | 52 | $312 |
| Pravastatin Sodium | 19 | $295 |
| Chlorthalidone | 17 | $279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $35 | $23,75921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 543 medical providers in Maryland.
Other medical in Ocean Pines
- Victoria TrottStevensville$94K
- Sarah SagorskyBaltimore$68K
- Emily GrisnikLeonardtown$62K
- Jennifer HamiltonBel Air$52K
- Kristina TrunnellFrederick$51K
- Karen ScottAnnapolis$49K
- Nicholas WunderAberdeen$40K
- Sarah JamiesonFrederick$34K
- Jayme WilliamsCatonsville$21K
- Megan PayneLutherville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.